Psychiatr. praxi 2019; 20(3): 133-135 | DOI: 10.36290/psy.2019.030
Trazodone once‑daily in depression
- Univerzita Karlova v Praze, Lékařská fakulta v Hradci Králové
- Psychiatrická klinika, Fakultní nemocnice Hradec Králové
A new extended release formula of trazodone oral tablets is available in the Czech Republic since 2015. It is intended for the treatment of depression of various etiology. It has beneficial effect in cases with comorbid anxiety and insomnia. The maximum potential of the full trazodone dose can be employed in such group of patients. Those could be treated by trazodone monotherapy without the necessity of using additional anxiolytic and hypnotic medication. Here presented case report depicts the full trazodone dose utilization as a first line treatment of depressive disorder. Application of the prolonged release trazodone form led to a fast anxiety and insomnia disappearance. It also enabled to stop the hypnotic and anxiolytic comedication.
Keywords: antidepressive agents, trazodone, depression
Published: October 11, 2019 Show citation
References
- Ravenelle F, Rahmouni M. Contramid(R): High-amylose starch for controlled drug delivery. Polysaccharides for drug delivery and pharmaceutical applications 2006; 934: 79-104.
Go to original source... - Šulcová A. Multimodální farmakologické působení trazodonu. Psychiatrie: časopis pro moderní psychiatrii 2015; 19(1): 49-52.
- Sheehan DV, Croft HA, Gossen ER, et al. Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study. Psychiatry (Edgmont) 2009; 6(5): 20-33.
Go to PubMed... - Salvatori E, Dato, G. D., Albert, U., Fagiolini, A., Kasper, S. 03 - A randomized, double-blind study comparing the efficacy and safety of trazodone OAD and venlafaxine XR for the treatment of patients with major depressive disorder. https://doi.org/10.26226MORRESSIER.5C642BEC9AE8FB00131CF65F, 2019. Go to original source...
- Ceskova E, Sedova M, Kellnerova R, et al. Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice. Pharmacology 2018; 102(3-4): 206-212. Go to original source... Go to PubMed...
- Juřica J. Trazodon - farmakologický profil multimodálního antidepresiva. Česká a slovenská psychiatrie : časopis České psychiatrické společnosti a Slovenskej psychiatrickej spoločnosti 2018; 114(2): 65-70.
- Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009; 14(10): 536-546. Go to original source... Go to PubMed...
- Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011; 44(6): 195-235. Go to original source... Go to PubMed...
- Mihara K, Yasui-Furukori N, Kondo T, et al. Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients. Ther Drug Monit 2002; 24(4): 563-566. Go to original source... Go to PubMed...
- Goeringer KE, Raymon L, Logan BK. Postmortem forensic toxicology of trazodone. Journal of Forensic Science 2000; 45(4): 850-856. Go to original source...
- Martinez MA, Ballesteros S, Sanchez de la Torre C, et al. Investigation of a fatality due to trazodone poisoning: case report and literature review. J Anal Toxicol 2005; 29(4): 262-226 Go to original source... Go to PubMed...